Bluejay Diagnostics, Inc. BJDX
Medical/Dental Instruments · IPO 2021 · data as of November 13, 2026
Bluejay Diagnostics, Inc. (BJDX) is a healthcare company listed in the US with a market value of about $3M.
Its overall Stock Analiz score is 0.8 out of 5 (weak). The strongest part is value (2/5); the weakest is future growth (0/5).
Key numbers: a P/E of 0.0, a 5-year average ROIC of -102%.
About Bluejay Diagnostics
Bluejay Diagnostics is listed in the US and classified in medical/dental instruments, IPO year 2021. It was profitable in 0 of the last 6 years in our data. Its share count rose by 71169% over three years (dilution for shareholders).
Score: 0.8 / 5
Checks passed
- P/E below 25
- P/E below the industry median
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
- 3-year free cash flow growth above 10% a year
- Strong R&D investment or growth above 20%
Valuation
Growth and quality
Financials, last 6 years
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | $249040 | — | — |
| Net income | -$7M | -$8M | -$10M | -$9M | -$3M | -$1M |
| Free cash flow | -$6M | -$8M | -$9M | -$9M | -$4M | — |
| EPS (diluted) | $-15.25 | $-456.75 | $-14525.92 | $-14753.35 | $-13121.19 | $-11841.08 |
| Net margin | — | — | — | -3733.1% | — | — |
| ROIC | -90.1% | -95.2% | -250.8% | -61.2% | -12.5% | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
Frequently asked questions
What is Bluejay Diagnostics’s P/E ratio?
About 0.0, based on the last twelve months of diluted earnings per share.
Does Bluejay Diagnostics pay a dividend?
Not currently.
Is Bluejay Diagnostics a good stock to buy?
We do not give buy or sell advice. Bluejay Diagnostics scores 0.8 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.